Table 2.

Expression of TGF-β markers by clinically important tumor characteristics among 623 breast cancer cases participating in the Polish Breast Cancer Study

	Intracellular-TGF-β1			Extracellular-TGF-β1			TGF-β2			TGF-β3			TGF-βR2			Phospho-SMAD2
	N	%	P value**	N	%	P value**	N	%	P value**	N	%	P value**	N	%	P value**	N	%	P value**
Positive	198	32		485	78		564	91		580	93		450	72		378	61
Tumor size N = 621
≤2 cm	94	30		244	78		289	93		298	96		242	78		191	61
>2 cm	103	33	0.42	239	77	0.68	273	88	0.04	280	90	0.01	206	66	0.002	186	60	0.72
Histological type N = 608
Ductal	157	31		383	76		452	89		470	93		370	73		309	61
Lobular	33	33	0.74	89	88	0.01	98	97	0.01	95	94	0.63	67	66	0.18	62	61	0.93
Tumor grade N = 623
Well differentiated	37	31		93	80		104	92		110	98		78	76		65	60
Moderately differentiated	95	33		212	77		248	91		259	95		182	71		148	59
Poorly differentiated	86	34	0.91	178	71	0.01	217	86	0.02	211	85	0.001	156	69	0.44	144	60	0.73
Axillary node metastasis = 610
Negative	108	31		264	77		306	89		319	93		240	70		196	57
Positive	88	33	0.66	211	79	0.45	245	92	0.19	248	93	0.81	197	74	0.24	174	65	0.03
ER N = 622
Negative	62	31		143	73		172	87		176	89		145	74		129	65
Positive	135	32	0.94	342	80	0.03	391	92	0.06	403	95	0.01	305	72	0.63	248	58	0.09
PR N = 622
Negative	90	31		213	73		256	88		265	91		204	70		173	59
Positive	107	32	0.71	272	82	0.01	307	93	0.04	314	95	0.06	246	74	0.24	204	62	0.58
HER2 N = 622
Negative	175	32		432	78		497	90		515	93		398	72		328	59
Positive	22	31	0.96	53	76	0.63	66	94	0.25	64	91	0.56	52	74	0.70	49	70	0.09
EGFR N = 621
Negative	152	30		401	78		463	91		478	94		365	71		302	59
Positive	45	41	0.02	83	75	0.49	99	90	0.84	100	91	0.32	84	76	0.29	74	67	0.11

%, Percent positive tumors

^**P value for χ² test